ReviewJournal of translational medicine2026
CD45 as a multifunctional target in immune regulation and therapeutic delivery.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCD45, a receptor-type protein tyrosine phosphatase broadly expressed on leukocytes, is a critical regulator of signaling thresholds and immune cell activation. Dysregulation of CD45 has been implicated in a range of immune-related diseases and malignancies. MAIN BODY: Recent advances have focused on modulating CD45 for disease treatment through various strategies, including regulating its expression level, structural conformation, and spatial membrane distribution. Beyond the immunomodulatory role, as a leukocyte-specific and broadly expressed biomarker, CD45 also has broad application in the field of drug delivery, such as the development of CD45 antibody-drug conjugates and a drug-loading site on live-cell carriers.
conclusionsThis review systematically summarizes the immunoregulatory mechanisms of CD45 across various immune cell subsets and discusses CD45-based therapeutic interventions and drug delivery strategies, bridging basic immunology with therapeutic advancement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.